Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15565230 | 0.75 | MAPT (0.36) | MAPTHIF1AALDH1A1L3MBTL1TP53 | |
| SCHEMBL22887951 | 0.75 | MAPT (0.33) | MAPTHIF1AALDH1A1L3MBTL1 | |
| SCHEMBL18366356 | 0.75 | MAPT (0.33) | MAPTHIF1AALDH1A1L3MBTL1 | |
| SCHEMBL23525062 | 0.74 | ALDH1A1 (0.35) | MAPTHIF1AALDH1A1L3MBTL1TP53 | |
| SCHEMBL16505741 | 0.74 | ALDH1A1 (0.36) | MAPTHIF1AALDH1A1L3MBTL1TP53 | |
| SCHEMBL2456370 | 0.74 | MAPT (0.42) | MAPTHIF1AALDH1A1L3MBTL1TP53 | |
| SCHEMBL2469602 | 0.72 | ALDH1A1 (0.38) | MAPTHIF1AALDH1A1L3MBTL1TP53 | |
| SCHEMBL18372761 | 0.71 | ALDH1A1 (0.36) | MAPTHIF1AALDH1A1L3MBTL1HTT | |
| SCHEMBL25495295 | 0.70 | MAPT (0.36) | MAPTHIF1AALDH1A1L3MBTL1TP53 | |
| SCHEMBL16572376 | 0.70 | ALDH1A1 (0.38) | MAPTALDH1A1L3MBTL1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2021124155-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | MAPT 505/4885HIF1A 1455/4885ALDH1A1 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.